ABX464 safe, effective in treating patients with ulcerative colitis

ABX464 safe, effective in treating patients with ulcerative colitis

Abivax announced positive phase 2b clinical induction and results for ABX464 in the treatment of patients with moderate to severe ulcerative colitis, according to a press release.In a randomized, double-blind, placebo-controlled trial, patients treated with once-daily ABX464 in each dosage group (25 mg, 50 mg and 100 mg) met the primary study endpoint of statistically significant reduction of Modified Mayo Score at 8-weeks. Further, compared with placebo, patients dosed with ABX464 demonstrated endoscopic improvement, clinical remission, clinical response and reduction of fecal calprotectin.Read More

Share on facebook
Share on twitter
Share on linkedin